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Whether the results of some drug studies could be used
to predict the results of other drug studies was examined
during serial electrophysiologic drug testing in patients
with sustained atrioventricular reentrant tachycardia.
The drugs studied were intravenous propranolol, 0.1
mg/kg; intravenous ouabain, 0.01 mg/kg; the combi-
nation of propranolol plus ouabain; intravenous pro-
cainamide, 0.75 to 1.5 g; oral quinidine, 1.2 to 2.4
g/day: and oral disopyramide, 0.8 to 1.6 g/day. Response
was inability to induce sustained tachycardia after
administration of a drug.
Responses due to increased anterograde limb refrac-
toriness. Six of 10 patients with response to propranolol
plus ouabain versus 0 of 9 patients without response to
this combination had response to propranolol alone (p
< 0.01). Seven of 14 patients with response to the com-
Patients with manifest or concealed preexcitation are prone
to atrioventricular (AV) reentrant paroxysmal tachycardia
in which the normal pathway is the anterograde limb and
the anomalous pathway is the retrograde limb (1,2). This
variety of paroxysmal tachycardia usually can be replicated
in the electrophysiology laboratory by programmed cardiac
stimulation (3). Electrophysiologic drug studies (4-6) have
been useful in patients with recurrent paroxysmal tachy-
cardia because they generally accurately predict the effec-
tiveness of drugs in preventing spontaneous recurrences of
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bination versus 0 of 9 patients without response to the
combination had response to ouabain alone (p < 0.05).
Responses due to increased retrograde limb refracto-
riness. Eight of 9 patients with response to procainamide
versus 2 of 17 patients without response to this drug had
response to quinidine (p < 0.01). There was not a sig-
nificant relation between response to procainamide and
response to disopyramide, ot between response to quin-
idine and response to disopyramide.
Anterograde limb versus retrograde limb. There was
not a significant relation between response to propran-
olol plus ouabain and response to any class I drug.
In conclusion, there are relations between drug re-
sponses during electrophysiologicstudies in patients with
atrioventricular reentrant tachycardia. Thus, it should
be possible to simplify these studies.
tachycardia; however, it requires several days to serially test
all of the available antiarrhythmic drugs.
In this study, we scrutinized the results of electrophys-
iologic drug studies in a series of patients with AV reentrant
tachycardia. We attempted to determine whether the results
of certain drug studies could be used to predict the results
of other drug studies (7). Our findings are germane to the
strategy employed in electrophysiologic drug studies in pa-
tients with AV reentrant tachycardia, and probably also to
empiric therapeutic drug trials in these patients.
Methods
Patient selection. The criteria for inclusion in the pres-
ent study were: I) referral to our laboratory because of
recurrent paroxysmal supraventricular arrhythmia; 2) per-
formance of a cardiac electrophysiologic study with dem-
onstration of a manifest or concealed anomalous AV path-
way; 3) induction of sustained orthodromic AV reentrant
tachycardia during control electrophysiologic studies; and
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4) electrophysiologic testing of two or more serial drugs for
ability to prevent induction of sustained tachycardia.
Characteristics of study group. Forty-seven patients
referred to our laboratory between January 1976 and Feb-
ruary 1982 met the criteria for inclusion. There were 32
male and 15 female patients, aged 12 to 72 years (mean ±
standard deviation, 38 ± 16). Thirteen patients (28%) had
heart disease, whereas 34 (72%) did not. Anomalous path-
ways were manifest in 33 patients (70%) and concealed in
14 patients (30%). Thirty-nine patients (83%) had docu-
mented paroxysmal supraventricular tachycardia (three of
these patients also had documented paroxysmal atrial fi-
brillation), whereas eight patients (17%) had only atrial
fibrillation documented. Thirty patients (64%) had been un-
successfully treated with one or more of the following an-
tiarrhythmic drugs before referral: propranolol, 25 patients;
digoxin, 19 patients; procainamide, 6 patients; quinidine, 8
patients; and disopyramide, 4 patients. During initial control
electrophysiologic studies (see later), the cycle lengths of
sustained AV tachycardia induced in the 47 patients ranged
from 240 to 510 ms (average 319 ± 48).
Initial control electrophysiologic study. This study was
performed in the postabsorptive, nonsedated state after all
cardioactive drugs had been discontinued for at least 5 half-
lives. Each patient gave informed written consent. A quad-
ripolar electrode catheter was advanced across the tricuspid
valve to record a His bundle electrogram. A hexapolar elec-
trode catheter was advanced to the right ventricular apex.
The distal two catheter tip electrodes were used to stimulate
the right ventricle, the middle two electrodes (10 ern) were
used to record a right atrial electrogram and the proximal
two electrodes (13.5 ern) were used to stimulate the right
atrium; additional catheters were used as needed to deter-
mine the location of the anomalous pathway (1 ,8-10). Sur-
face electrocardiographic leads, I, II, III and VI and intra-
cardiac electrograms were recorded simultaneously on a
multichannel oscilloscopic recorder (Electronics for Medi-
cine DR-12 or VR-16) at a paper speed of 100 or 250
mm/s. Pacing stimuli were provided by a programmable
digital stimulator (M. Bloom) with a strength of approxi-
mately twice the diastolic threshold and a duration of 2 ms.
The stimulation protocol included incremental atrial pac-
ing, atrial extrastimulus testing during sinus rhythm and at
one or more shorter (atrial) paced cycle lengths, incremental
ventricular pacing, and ventricular extrastimulus testing at
one or more ventricular paced cycle lengths. Two atrial
extrastimuli were occasionally required for induction or ter-
mination of paraxysmal tachycardia. Orthodromic AV reen-
trant tachycardia, reflecting anterograde conduction over the
normal pathway and retrograde conduction over the anom-
alous pathway, was diagnosed using previously described
criteria (3) . By study design, all patients had inducible
tachycardia that was sustained, that is, lasting longer than
2 minutes and requiring conversion with atrial stimulation.
Drug studies. After the initial control electrophysio-
logic study, an intravenous drug (see later) was administered
and the stimulation protocol was repeated. At the end of
the first day of study, the hexapolar electrode catheter was
secured in a position suitable for both atrial and ventricular
stimulation, and other catheters were removed. On subse-
quent days, additional control studies were performed to
confirm that sustained tachycardia could be induced before
other intravenous drugs were administered. Control studies
could not be performed on days when oral drugs were
administered.
Each administered drug was evaluated fo r ability to pre-
vent induction of sustained AVreentrant tachycardia . After
administration of a drug, response was defined as inability
to induce sustained tachycardia and nonresponse was de-
fined as continued ability to induce sustained tachycardia.
The fo llowing drugs were evaluated for their ability to
prevent induction of sustained tachycardia by increasing
ref ractoriness of the anterograde limb (A V node): intrave-
nous propranolol, 0.1 rng/kg, tested in 25 patients 20 min-
utes after administration; intravenous ouabain, 0.0 I rug/kg,
tested in 24 patients 30 minutes after administration; and
the combination of intravenous propranolol plus intravenous
ouabain (one drug was administered after the other drug had
been tested) tested in 35 patients. Response to these drugs
was manifest by induced reentrance, which always termi-
nated spontaneously with an atrial depolarization not fol-
lowed by His bundle (or ventricular) depolarization. In this
situation, the increase in anterograde AV nodal refractori-
ness was confi rmed by demonstration of a marked increase
in the maximal atrial-paced cycle length at which second
degree AV block occurred in the normal pathway ( I I). This
demonstration was not possible when anterograde anoma-
lous pathway refractoriness was short.
The class I drugs evaluated fo r their ability to prevent
induction of sustained tachycardia by increasing refracto-
riness of the retrogra de limb (anomalous pathway) were:
intravenous procainarnide. 750 to 1,500 mg (mean 983) in
40 patients; oral quinidine. 1.2 to 2.4 g/day (mean 1.7) in
27 patients; and oral disopyrarnidc, 0.8 to 1.6 g/day (mean
1.2) in 22 patients. Response to these drugs was manifest
by induced reentrance, which always terminated sponta-
neously with a ventricular depolarization not followed by
atrial depolarization, or by an inability to induce AV reen-
trant atrial echoes despite achievement of anterograde nor-
mal pathway conduction times that had been sufficient to
induce tachycardia during control studies. In these situa-
tions, the increase in retrograde anomalous pathway refrac-
toriness was confi rmed by demonstration of a marked in-
crease in the maximal ventricular-paced cycle length at which
second degree block occurred in the anomalous pathway
(II).
In each of the 47 pati ents, 2 to 6 (mean 3.7) drugs or
drug combinations were tested as described . Failure to test
JACC Vol 2. No 2
August 19113 '345- 50
BAUERNFEIND ET AL
DRUG RESPONSES IN AV REENTRANT TACHYCARDIA
347
Figure I. Relation between response to the combination of pro-
pranolol (PROP) plus ouabain (OUAB ) and response (left) to pro-
pranolol alone and ouabain alone (right) . Six of 10 patients (pts)
with response to the combination versu s 0 of 9 patients with non-
response 10 the combination had response 10 propranolol alone
(probability [p) < 0.01). Similarly , 7 of 14 patients with response
to the combination versus 0 of 9 patients with nonre sponse to the
combination had respon se to ouabain alone (p < 0.05).
zyme immunoassays (Emit-cad, SYVA Co.) with blood
drawn at the completion of testing. The 13 patients with
response to procainamide received 750 to 1,500 mg (mean
± standard error 981 ± 72) of this drug and II of these
patients had serum levels of 3.4 to 12.8 JLg/ml (mean 6.7
± 0.8), whereas the 27 patients with nonresponse received
750 to 1,500 mg (mean 985 ± 54) and 19 of these patients
had serum levels of 2.5 to 22.5 JLglml (mean 6.6 ± l .I ).
The 10 patients with response to quinidine received 1.2 to
2.4 g/day (mean 1.6 ± 0.1) of this drug and 8 of these
patients had serum levels of 1.6 to 4.0 JLg/ml (mean 2.6 ±
0.3), whereas the 17 patients with nonresponse received 1.2
to 2.4 g/day (mean 1.7 ± 0.1) and 12 of these patients had
serum levels of 1.5 to 12.1 Jlg/ml (mean 3.8 ± 0.8) . The
II patients with response to disopyramide received 0.8 to
1.6 g/day (mean 1.2 ± 0.1) of this drug and 3 of these
patients had serum levels of 4.0 to 5.2 Jlg/ml (mean 4.7 ±
0.4 ), whereas the II patients with nonresponse received 0.8
to 1.6 g/day (mean 1.2 ± 0.1) and 2 of these patients had
serum levels of 3.5 and 5.0 JLg/ml , respectively.
We tested for a relation between response to one class
I drug and response to other class I drugs . Twenty-six
patients given procainamide were also given quinidine. Of
nine patients with response to procainamide, eight (89%)
had response to quinidine. In contrast, of 17 patients with
nonresponse to procainamide, only 2 (12%) had response
to quinidine (p < 0.01) . Twenty patients given procain-
amide were also given disopyramide. Of 6 patients with
response to procainarnide, 5 (83%) had response to diso-
o Nonresponse
l?Jl Response 9 pts 9pts
PROP + OUAB
Nonrupond.s
PROP QUAB
.<o.o.~
PROP+ OUAB
Responders
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Results
Anterograde limb. Seven (28%) of 25 patients had re-
sponse to propranolol alone, 7 (29%) of 24 patients had
response to ouabain alone and 17 (49%) of 35 patients had
response to the combination of propranolol plus ouabain.
We tested for relations between response to the combination
of propranolol plus ouabain and response to propranolol
alone or ouabain alone. In 19 patients in whom the com-
binationof propranolol plus ouabain was tested, propranolol
alone was also tested. Of 10 patients with response to the
combination, 6 (60%) had response to propranolol alone.
In contrast, of the nine patients with nonresponse to the
combination of drugs, none had response to propranolol
alone (probability [p] < 0.01 ) (Fig. I). Twenty-three pa-
tients given the combination of propranolol plus ouabain
also received ouabain alone. Of 14 patients with response
to the combination, 7 (50%) had response to ouabain alone.
In contrast, of the nine patients with nonresponse to the
combination, none had response to ouabain alone (p < 0.05)
(Fig. I). We also tested for a relation between response to
propranolol alone and response to ouabain alone; however,
only eight patients were relevant to this analysis. One of
three patients with response to propranolol and one of fi ve
patients with nonresponse to propranolol had response to
ouabain (not signifi cant).
Retrograde limb. Thirteen (32%) of 40 patients had
response to procainamide, 10 (37%) of 27 patients had re-
sponse to quinidine, and II (50%) of 22 patients had re-
sponse to disopyramide. Although the administered dosages
of class I drugs varied, there was no relation between re-
sponse to these drugs and either dosage administered or
serum levels, which were determined by quantitative en-
some drugs in some patients related to the following. l ) We
did not test quinidine before April 1977 or disopyramide
before August 1978. 2) Some patients could not tolerate
administration of oral quinidine or oral disopyramide. 3)
We sometimes elected not to test ouabain or propranolol in
patients with documented paroxysmal atrial fibrillation and
short anterograde anomalous pathway refractoriness.
4) Occasionally, the hexapolar catheter had to be removed
before all drugs had been tested. 5) We frequently elected
not to test propranolol alone or ouabain alone in patients
who did not respond to the combination of propranolol plus
ouabain (see Results). In general, we did not consider a
clinical history of refractoriness to a drug to be a reason not
to test the drug.
Statistical analyses. Comparisons between two groups
of patients with respect to the presence or absence of specific
attributes were made by 2 x 2 chi-square analysis with
Yates' correction (when appropriate). Comparisons between
two groups of patients with respect to numerical data were
made by t test for unpaired data.
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pyramide, whereas of 14 patients with nonresponse to pro-
cainamide, 6 (43%) had response to disopyramide (differ-
ence not significant). Twenty patients given quinidine were
also given disopyramide. Of 6 patients with response to
quinidine, 5 (83%) had response to disopyramide, whereas
of 14 patients with nonresponse to quinidine, 6 (43%) had
response to disopyramide (not significant).
Anterograde limb versus retrograde limb. Finally, we
tested for a relation between response to the combination
of propranolol plus ouabain (anterograde limb) and response
to class 1drugs (retrograde limb). Thirty-one patients tested
with the combination were also tested with one or more
class 1 drugs. Of 14 patients with response to the combi-
nation, 7 (50%) had response to a class I drug, whereas of
17 patients with nonresponse to the combination, 9 (53%)
had response to a class 1 drug (not significant) (Fig. 2).
Thus, there was no relation between response to the com-
bination of propranolol plus ouabain and response to any
class I drug. In addition, there was no relation between
response to the combination of propranolol plus ouabain and
response to any of the individual class 1drugs.
Discussion
Sustained atrioventricular reentrant paroxysmal tachy-
cardia can be induced by programmed cardiac stimulation
in almost all patients with preexcitation complicated by re-
current paroxysmal tachycardia and in most patients with
preexcitation complicated by recurrent paroxysmal atrial fi-
brillation (it is likely that paroxysmal tachycardia is fre-
quently the rhythm that initiates atrial fibrillation in these
latter patients) (3,12-14). The ability to replicate sustained
paroxysmal tachycardia in the electrophysiology laboratory
has been used to study the effects of various drugs on in-
Figure 2. Absence of a relat ion between response to the combi-
nation of propranolol plus ouabain and response to class I drugs.
Seven of 14 patients with response to the combination and 8 of
17 patients with nonresponse to the combination had response to
class I drugs. NS == not significant.
PRQP+ QUAB PRQP+ QUAB
Rllsponders Nonresponders
apts
(47% 0 Nonresponse to class I drulis
~ Response to class I drulis
duction and sustenance of tachycardia. After administration
of a drug, continued ability to induce sustained tachycardia
is considered a nonresponse to the drug, whereas inability
to induce sustained tachycardia is considered a response (4-
6); however, the results of these studies vary from patient
to patient. Some, but not all, patients have response to beta-
blocking adrenergic agents, digitalis or verapamil because
of increased anterograde normal pathway refractoriness.
Others, but not all, have response to procainamide, quini-
dine or disopyramide because of increased retrograde anom-
alous pathway refractoriness (4,6, 15- 21). These drug stud-
ies appear to be clinically relevant because long-term
administration of a drug to which there was response in the
laboratory generally has prevented spontaneous recurrences
of paroxysmal tachycardia (4-6 ) .
For the past 6 years, we have tried to serially test each
of the fi ve conventional antiarrhythmic agents (verapamil
had not been approved) and also the combination of pro-
pranolol plus ouabain in patients with inducible sustained
paroxysmal tachycardia. This strategy has enabled us to
delineate one or more drugs likely to be effective therapy,
or to demonstrate nonresponse to each of the available drugs
(in which case other modes of therapy have been consid-
ered). However, this strategy has required the performance
of six drug studies over a minimal period of 5 days. Thus,
our drug studies have been time-consuming and expensive
and have posed a risk of phlebitis or infection at the site of
the catheter insertion. In the present study, we reevaluated
our strategy. We asked whether each of the six drug studies
is necessary, or whether the results of some drug studies
can be used to predict the results of other drug studies. We
tried to determine the minimal numberof drug studies needed
to fully characterize the pattern of drug responses.
Propranolol plus ouabain versus class I drugs. We
did not find a relation between response to the combination
of propranolol plus ouabain and response to class I drugs.
This suggests that the results with drugs that act on the
anterograde limb cannot be used to predict the results with
drugs that act on the retrograde limb (and vice versa). Thus,
at least two studies are needed to characterize the pattern
of drug responses in a patient with paroxysmal tachycardia.
Propranolol plus ouabain versus each drug alone. With
respect to drugs that act on the anterograde limb, we found
that patients with response to the combination of propranolol
plus ouabain frequently had response to propranolol alone
or to ouabain alone, whereas patients with nonresponse to
the combination did not respond to either propranolol or
ouabain alone. These find ings suggest that it is useful to
test the combination of propranolol plus ouabain in patients
with paroxysmal tachycardia. If there is response to this
combination, then testing of propranolol alone and ouabain
alone can be performed. However, if there is nonresponse
to the combination, then testing of the individual drugs is
probably not worthwhile.
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Procainamide versus quinidine. With respect to drugs
that act on the retrograde limb, we found a strong concordant
relation between response to procainamide and response to
quinidine. Almost all patients with response to procainamide
had response to quinidine, whereas only a few patients with
nonresponse to procainamide had response to quinidine.
This suggests that it is not necessary to test both procain-
amide and quinidine in patients with paroxysmal tachy-
cardia. For practical purposes, the result obtained with one
of these drugs can be applied to the other drug as well.
Procainamide or quinidine versus disopyramide. The
absence of significant relations between response to pro-
cainamide and response to disopyramide, and between re-
sponse to quinidine and response to disopyrarnide, may have
been due to the relatively small number of patients tested
with each of these drug pairs. We did note that patients who
responded to procainamide or quinidine usually responded
to disopyramide. However, we also found that patients with
nonresponse to procainamide or quinidine frequently re-
sponded to disopyramide. This latter finding may suggest
that disopyramide is more potent than procainamide or quin-
idine, or that the dosages of disopyramide tested were rel-
atively large, Although it is difficult to compare a dosage
or serum level of disopyramide with a dosage or serum level
of procainamide or quinidine, we have found that the dos-
ages of disopyramide that we employ frequently cause sig-
nificant side effects (22). Thus, our results with disopyr-
amide might have been more relevant (and more concordant
with our results for procainamide and quinidine) if we had
tested smaller dosages of this drug.
Correlation of drug response to dosage and serum
levels and to electrophysiologic properties. In the present
study, we found that some patients had response and others
had nonresponse to identical dosages of propranolol and
ouabain alone or in combination. Furthermore, although we
tested variable dosages of class I agents, we found that
response to these drugs did not correlate with either the
dosages administered or serum levels. Each of these findings
suggests that the result of testing a drug relates not only to
the amount of drug administered but also to biologic vari-
ables. Our concordant results with respect to drugs that act
on the anterograde limb and with respect to drugs that act
on the retrograde limb presumably were related to (mea-
surable or unmeasurable) electrophysiologic properties of
the normal pathway and the anomalous pathway, respec-
tively. Our finding that results with drugs that act on the
anterograde limb cannot be used to predict results with drugs
that act on the retrograde limb is consistent with this
hypothesis.
Clinical implications. We have found several situations
in which the result of electrophysiologic testing with one
drug can be used to predict the result of testing with another
drug. Thus, it should be possible to simplify electrophysi-
ologic drug studies in patients with atrioventricular reentrant
paroxysmal tachycardia. Our findings are probably also ger-
mane to empiric therapeutic drug trials in patients with this
variety of paroxysmal tachycardia.
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